Chaney Ojinnaka 1/24/26 Chaney Ojinnaka 1/24/26

CMS Signals Bold Bet on Innovation: Pricing Analysis of 40 New Diagnostic Tests

Read More

Chaney Ojinnaka 12/21/25 Chaney Ojinnaka 12/21/25

FDA’s New RWE Pivot Makes AI Provenance the New Gold Standard

Read More

Chaney Ojinnaka 12/12/25 Chaney Ojinnaka 12/12/25

FDA AI Medical Devices List: Approvals vs. Commercial Reality

Read More

Chaney Ojinnaka 12/2/25 Chaney Ojinnaka 12/2/25

OBBBA – What Drug Manufacturers Need to Know

Read More

Chaney Ojinnaka 11/18/25 Chaney Ojinnaka 11/18/25

Beyond Compliance: De-Risking US Market Entry via FDA Clinical Trial Diversity Requirements

Read More

Chaney Ojinnaka 11/16/25 Chaney Ojinnaka 11/16/25

Free and Low-Cost RWE Data: From Clinical to Commercial Operations

Read More

Chaney Ojinnaka 10/31/25 Chaney Ojinnaka 10/31/25

Towards AI: Federated Models in Life Sciences

Read More